Drug
TD 8236
TD 8236: highest development phase Phase 2, developed by Theravance Biopharma. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Theravance Biopharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| TD-8236 NCT04150341 | Phase 2 | Asthma |
| TD-8236 NCT03652038 | Phase 1 | Asthma |
Latest
No recent events.
Follow TD 8236 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.